New findings from a study by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, show that U.S. incidence rates for aggressive subtypes of uterine cancer rose rapidly among women ages 30 to 79 from 2000 to 2015. The findings also reveal racial disparities, including higher incidence of these aggressive subtypes and poorer survival—irrespective of subtype and cancer stage—among non-Hispanic black women than among women in other racial/ethnic groups. The study, published May 22, 2019 in the Journal of Clinical Oncology, used population data from NCI’s Surveillance, Epidemiology, and End Results (SEER) database to evaluate trends…
Author: Brett Johnson
The Cancer Progress Report delivers crisp headlines of progress at emerging companies developing, in many cases, breakthroughs. It is a fast and efficient must read for anyone serious in the field. For companies it provides an economical means to accomplish the critical function of reaching and keeping the important informed as to progress. Editorial Content has three themes: Introductions to New Members Introduction to the company and what makes it unique. This 40 words linked to the Altru Cancer website and the company site for a full profile. Ongoing Coverage Member Progress. Update on newsworthy developments. Headline and first sentence…
A new diagnostic technology can predict how patients will respond different drugs or drug combinations before the patients take the drugs. Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer. This revolutionary diagnostic test will enable oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells. See Travera’s Profile.
“For me, this is one of the great honors of my research career,” says Dr. Ronald DePinho, who in 2009 won the prestigious Szent-Györgyi Prize for Progress in Cancer Research—and who has a touching personal tie to the namesake of the accolade. “I had the privilege of meeting Dr. Szent-Györgyi in my younger years, and was quite honored to later receive an award that bears his name.” It is natural to assume that to win the Szent-Györgyi Prize, one of oncology’s top laurels, a researcher must unravel a Gordian knot of genetic codes or discover some heretofore unknown cellular process.…
Immuno-oncology focusing on women’s cancers Technology Although cancer therapies have been developed that stimulate the immune system, these approaches have often proven ineffective because the cancers remain invisible to the immune system. Cancers cannot induce an immune response because they no longer express sufficient levels of key proteins on their cell surface. Antigen presentation is impaired thus presenting a weakened signal to which the cellular immune system can respond. The company’ peptide antigens can stimulate both T-killer cells and T-helper cells. When combined with its Polystart expression vector provides a competitive edge in the in vivo T-cell vaccine sector. Clinical…
Technology CEL-SCI Corporation is a late-stage biopharmaceutical company developing products for life-threatening diseases (such as cancer and infectious diseases). Its lead pipeline product – Multikine investigational immunotherapy (Leukocyte Interleukin, Injection) is a complex biological product containing a patented mixture of pro-inflammatory cytokines, lyphokines and chemokines. The aim of the Multikine immunotherapy treatment regimen is to break tumor-tolerance and up-end the tumor’s defense mechanisms by increasing tumor–specific infiltrating T-cells, NK cells and Neutrophils in the tumor and its microenvironment. The Multikine regimen is administered prior to any other therapy (immediately after diagnosis) when the immune system is thought to be most amenable…
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company’s discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune cells, such as T-lymphocytes that are isolated from the patient or retrieved from allogeneic immune cell banks, and then expanded and in some cases processed to express tumor-binding receptors. Our approach introduces a new and important step in ex-vivo processing of the immune cells where sd-rxRNA is used to eliminate the expression…
Head & Neck Cancer Report Launched The first chapter of the Cancer Impact Guide includes an overall summary of the current approach to diagnosis and standard of care and profiles of companies. Visit the Head and Neck section of the Cancer Impact Guide. Several promising public companies with catalysts on the horizon were identified including CEL-SCI, Soligenix and CytRx all who have become members of the Cancer Consortium, a global effort to increase collaboration of organizations of all types to advance progress in cancer. Head and neck cancer researchers around the globe continue to make steady progress toward developing effective…